It may well be that the world takes two paths to fight the coronavirus causing COVID-19. The first group could continue vaccinating and taking care. While the second might put their trust in their immunity, and medication if they caught the disease. Pfizer is one of several companies chasing both markets. Breaking news is their tablet to fight the worst of COVID has showed positive results during trials.
Trial Shows 89% Reduction in Hospitalization and Death
Pfizer has been trialing their new tablet among volunteers. Their research is still ongoing. However, they released an interim analysis after their tablet to fight the worst of COVID produced these highly positive results:
- There was an 89% reduced likelihood of going to hospital after their subjects caught the illness.
- Moreover, those volunteers were also 89% less likely to die from the pandemic disease.
This was good enough for Pfizer. They stopped the trial and announced they would ask U.S. Food and Drug Administration FDA to approve their product. However, they did this in a rush without sharing data with scientists. But they say they will reveal more when they apply for emergency use. This may well be before Thanksgiving according to CNN Health.
More About the Pfizer Tablet to Fight the Worst of COVID
Pfizer tested their products on 389 adults at high risk of severe symptoms, after they caught COVID-19. They divided them in two categories. One received their new tablet alongside ritonavir. This is another medication for inhibiting human immunodeficiency virus (HIV). The other group received inactive placebos.
1… Just 3 of the 389 patients who received the experimental treatment went to hospital within four weeks.
2… This was a far better result than for the 29 placebo patients who ended up in hospital during that period.
Moreover, seven of the latter group perished from the disease. While all those receiving the new medication Paxlovid, together with ritonavir survived. We are making good progress!
Breaking News
High-Risk Gene for COVID-19 Discovered
Is UK Willing to Trade Some COVID-19 Risks
Preview Image: COVID Fatality Rate by Age
